Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/HNRNPA2B1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/HNRNPA2B1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/HNRNPA2B1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/HNRNPA2B1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/HNRNPA2B1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/HNRNPA2B1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/HNRNPA2B1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/HNRNPA2B1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/HNRNPA2B1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/HNRNPA2B1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/HNRNPA2B1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:200125231 | Oral cavity | NEOLP | positive regulation of chromosome organization | 23/2005 | 82/18723 | 1.07e-05 | 1.98e-04 | 23 |
GO:005102831 | Oral cavity | NEOLP | mRNA transport | 31/2005 | 130/18723 | 1.38e-05 | 2.43e-04 | 31 |
GO:000072331 | Oral cavity | NEOLP | telomere maintenance | 31/2005 | 131/18723 | 1.62e-05 | 2.79e-04 | 31 |
GO:003220431 | Oral cavity | NEOLP | regulation of telomere maintenance | 22/2005 | 80/18723 | 2.32e-05 | 3.72e-04 | 22 |
GO:005105231 | Oral cavity | NEOLP | regulation of DNA metabolic process | 63/2005 | 359/18723 | 5.48e-05 | 7.44e-04 | 63 |
GO:003304431 | Oral cavity | NEOLP | regulation of chromosome organization | 38/2005 | 187/18723 | 7.52e-05 | 9.71e-04 | 38 |
GO:005105431 | Oral cavity | NEOLP | positive regulation of DNA metabolic process | 40/2005 | 201/18723 | 8.01e-05 | 1.01e-03 | 40 |
GO:003220622 | Oral cavity | NEOLP | positive regulation of telomere maintenance | 15/2005 | 52/18723 | 2.53e-04 | 2.59e-03 | 15 |
GO:001083332 | Oral cavity | NEOLP | telomere maintenance via telomere lengthening | 20/2005 | 81/18723 | 2.69e-04 | 2.71e-03 | 20 |
GO:190435817 | Oral cavity | NEOLP | positive regulation of telomere maintenance via telomere lengthening | 12/2005 | 37/18723 | 3.15e-04 | 3.09e-03 | 12 |
GO:190435631 | Oral cavity | NEOLP | regulation of telomere maintenance via telomere lengthening | 16/2005 | 61/18723 | 5.23e-04 | 4.61e-03 | 16 |
GO:003220031 | Oral cavity | NEOLP | telomere organization | 31/2005 | 159/18723 | 6.95e-04 | 5.76e-03 | 31 |
GO:200027832 | Oral cavity | NEOLP | regulation of DNA biosynthetic process | 23/2005 | 106/18723 | 7.22e-04 | 5.93e-03 | 23 |
GO:003519631 | Oral cavity | NEOLP | production of miRNAs involved in gene silencing by miRNA | 14/2005 | 52/18723 | 8.66e-04 | 6.83e-03 | 14 |
GO:005197232 | Oral cavity | NEOLP | regulation of telomerase activity | 13/2005 | 47/18723 | 9.97e-04 | 7.65e-03 | 13 |
GO:000640531 | Oral cavity | NEOLP | RNA export from nucleus | 19/2005 | 84/18723 | 1.20e-03 | 8.85e-03 | 19 |
GO:003105031 | Oral cavity | NEOLP | dsRNA processing | 14/2005 | 54/18723 | 1.30e-03 | 9.43e-03 | 14 |
GO:007091831 | Oral cavity | NEOLP | production of small RNA involved in gene silencing by RNA | 14/2005 | 54/18723 | 1.30e-03 | 9.43e-03 | 14 |
GO:00310531 | Oral cavity | NEOLP | primary miRNA processing | 6/2005 | 13/18723 | 1.32e-03 | 9.48e-03 | 6 |
GO:00714263 | Oral cavity | NEOLP | ribonucleoprotein complex export from nucleus | 17/2005 | 76/18723 | 2.41e-03 | 1.54e-02 | 17 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501416 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
hsa0501417 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
hsa0501423 | Breast | IDC | Amyotrophic lateral sclerosis | 102/867 | 364/8465 | 1.29e-22 | 5.22e-21 | 3.91e-21 | 102 |
hsa0501433 | Breast | IDC | Amyotrophic lateral sclerosis | 102/867 | 364/8465 | 1.29e-22 | 5.22e-21 | 3.91e-21 | 102 |
hsa0501443 | Breast | DCIS | Amyotrophic lateral sclerosis | 101/846 | 364/8465 | 7.14e-23 | 2.88e-21 | 2.12e-21 | 101 |
hsa0501453 | Breast | DCIS | Amyotrophic lateral sclerosis | 101/846 | 364/8465 | 7.14e-23 | 2.88e-21 | 2.12e-21 | 101 |
hsa05014 | Colorectum | AD | Amyotrophic lateral sclerosis | 164/2092 | 364/8465 | 4.28e-18 | 1.27e-16 | 8.09e-17 | 164 |
hsa050141 | Colorectum | AD | Amyotrophic lateral sclerosis | 164/2092 | 364/8465 | 4.28e-18 | 1.27e-16 | 8.09e-17 | 164 |
hsa050142 | Colorectum | SER | Amyotrophic lateral sclerosis | 138/1580 | 364/8465 | 9.89e-19 | 2.99e-17 | 2.17e-17 | 138 |
hsa050143 | Colorectum | SER | Amyotrophic lateral sclerosis | 138/1580 | 364/8465 | 9.89e-19 | 2.99e-17 | 2.17e-17 | 138 |
hsa050144 | Colorectum | MSS | Amyotrophic lateral sclerosis | 156/1875 | 364/8465 | 1.43e-19 | 4.62e-18 | 2.83e-18 | 156 |
hsa050145 | Colorectum | MSS | Amyotrophic lateral sclerosis | 156/1875 | 364/8465 | 1.43e-19 | 4.62e-18 | 2.83e-18 | 156 |
hsa050146 | Colorectum | MSI-H | Amyotrophic lateral sclerosis | 95/797 | 364/8465 | 2.31e-21 | 1.50e-19 | 1.26e-19 | 95 |
hsa050147 | Colorectum | MSI-H | Amyotrophic lateral sclerosis | 95/797 | 364/8465 | 2.31e-21 | 1.50e-19 | 1.26e-19 | 95 |
hsa050148 | Colorectum | FAP | Amyotrophic lateral sclerosis | 91/1404 | 364/8465 | 1.84e-05 | 2.36e-04 | 1.44e-04 | 91 |
hsa050149 | Colorectum | FAP | Amyotrophic lateral sclerosis | 91/1404 | 364/8465 | 1.84e-05 | 2.36e-04 | 1.44e-04 | 91 |
hsa0501420 | Endometrium | AEH | Amyotrophic lateral sclerosis | 123/1197 | 364/8465 | 2.17e-22 | 7.82e-21 | 5.72e-21 | 123 |
hsa05014110 | Endometrium | AEH | Amyotrophic lateral sclerosis | 123/1197 | 364/8465 | 2.17e-22 | 7.82e-21 | 5.72e-21 | 123 |
hsa0501425 | Endometrium | EEC | Amyotrophic lateral sclerosis | 128/1237 | 364/8465 | 9.83e-24 | 4.04e-22 | 3.01e-22 | 128 |
hsa0501435 | Endometrium | EEC | Amyotrophic lateral sclerosis | 128/1237 | 364/8465 | 9.83e-24 | 4.04e-22 | 3.01e-22 | 128 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HNRNPA2B1 | SNV | Missense_Mutation | | c.951N>C | p.Lys317Asn | p.K317N | P22626 | protein_coding | deleterious(0.03) | benign(0.264) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
HNRNPA2B1 | SNV | Missense_Mutation | | c.209N>T | p.Ser70Leu | p.S70L | P22626 | protein_coding | deleterious(0.03) | probably_damaging(0.975) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
HNRNPA2B1 | SNV | Missense_Mutation | | c.124G>C | p.Glu42Gln | p.E42Q | P22626 | protein_coding | tolerated(0.13) | benign(0.192) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
HNRNPA2B1 | SNV | Missense_Mutation | | c.46N>A | p.Glu16Lys | p.E16K | P22626 | protein_coding | deleterious(0.01) | probably_damaging(0.932) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
HNRNPA2B1 | SNV | Missense_Mutation | novel | c.869A>G | p.Tyr290Cys | p.Y290C | P22626 | protein_coding | tolerated(0.17) | benign(0.339) | TCGA-OL-A5RW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
HNRNPA2B1 | SNV | Missense_Mutation | novel | c.353G>A | p.Gly118Glu | p.G118E | P22626 | protein_coding | deleterious(0.01) | probably_damaging(0.954) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
HNRNPA2B1 | insertion | In_Frame_Ins | novel | c.356_357insGAACAAAAA | p.Ile119delinsMetAsnLysAsn | p.I119delinsMNKN | P22626 | protein_coding | | | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD |
HNRNPA2B1 | SNV | Missense_Mutation | | c.185N>T | p.Arg62Ile | p.R62I | P22626 | protein_coding | deleterious(0.01) | probably_damaging(0.975) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
HNRNPA2B1 | SNV | Missense_Mutation | | c.565N>C | p.Ser189Pro | p.S189P | P22626 | protein_coding | tolerated(0.08) | probably_damaging(0.927) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
HNRNPA2B1 | SNV | Missense_Mutation | novel | c.389A>C | p.Asp130Ala | p.D130A | P22626 | protein_coding | deleterious(0) | possibly_damaging(0.467) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |